Literature DB >> 7263845

Radioimmunological determination of urinary melatonin in humans: correlation with plasma levels and typical 24-hour rhythmicity.

U Lang, M Kornemark, M L Aubert, L Paunier, P C Sizonenko.   

Abstract

To study melatonin secretion by a gentle noninvasive method, a simple and quick RIA procedure to analyze melatonin in small urine volumes has been developed. Urinary extracts were prepurified by alkaline washes, and melatonin content was determined by RIA. The specificity of urinary melatonin determinations was confirmed by both thin layer chromatography and by gas chromatography-mass spectrometry. In the present study, we compared the amount of melatonin excreted in urine with plasma levels in 140 specimens from 13 adult volunteers. Comparisons showed a very good correlation between plasma levels at midnight and nocturnal excretion of urine, indicating the biological relevance of melatonin determination in urine. Our studies show further that urinary melatonin excretion displays the characteristic circadian rhythm usually observed in plasma. On the average, melatonin excretion is greatest between 2300--0300 h. The total 24-h excretion of melatonin varies considerably among different individuals.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7263845     DOI: 10.1210/jcem-53-3-645

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

1.  Sleep duration, spot urinary 6-sulfatoxymelatonin levels and risk of breast cancer among Chinese women in Singapore.

Authors:  Anna H Wu; Frank Z Stanczyk; Renwei Wang; Woon-Puay Koh; Jian-Min Yuan; Mimi C Yu
Journal:  Int J Cancer       Date:  2012-06-28       Impact factor: 7.396

2.  Pharmacokinetics of melatonin in preterm infants.

Authors:  Nazakat M Merchant; Denis V Azzopardi; Ahmed F Hawwa; James C McElnay; Benita Middleton; J Arendt; Tomoki Arichi; Pierre Gressens; A David Edwards
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

3.  Elevated daytime melatonin concentrations in autism: A pilot study.

Authors:  Edward R Ritvo; Riva Ritvo; Arthur Yuwiler; Anne Brothers; B J Freeman; Selma Plotkin
Journal:  Eur Child Adolesc Psychiatry       Date:  1993-04       Impact factor: 4.785

4.  Urinary melatonin concentration and the risk of breast cancer in Nurses' Health Study II.

Authors:  Susan B Brown; Susan E Hankinson; A Heather Eliassen; Katherine W Reeves; Jing Qian; Kathleen F Arcaro; Lani R Wegrzyn; Walter C Willett; Eva S Schernhammer
Journal:  Am J Epidemiol       Date:  2015-01-13       Impact factor: 4.897

5.  Melatonin secretion and the incidence of type 2 diabetes.

Authors:  Ciaran J McMullan; Eva S Schernhammer; Eric B Rimm; Frank B Hu; John P Forman
Journal:  JAMA       Date:  2013-04-03       Impact factor: 56.272

6.  Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort.

Authors:  Eva S Schernhammer; Franco Berrino; Vittorio Krogh; Giorgio Secreto; Andrea Micheli; Elisabetta Venturelli; Sara Grioni; Christopher T Sempos; Adalberto Cavalleri; Holger J Schünemann; Sabrina Strano; Paola Muti
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-03       Impact factor: 4.254

Review 7.  Clinical aspects of the melatonin action: impact of development, aging, and puberty, involvement of melatonin in psychiatric disease and importance of neuroimmunoendocrine interactions.

Authors:  F Waldhauser; B Ehrhart; E Förster
Journal:  Experientia       Date:  1993-08-15

8.  Urinary melatonin and risk of incident hypertension among young women.

Authors:  John P Forman; Gary C Curhan; Eva S Schernhammer
Journal:  J Hypertens       Date:  2010-03       Impact factor: 4.844

9.  Urine melatonin in alcoholic patients: a marker of alcohol abuse?

Authors:  G Murialdo; U Filippi; P Costelli; S Fonzi; P Bo; A Polleri; F Savoldi
Journal:  J Endocrinol Invest       Date:  1991-06       Impact factor: 4.256

10.  Melatonin: data consistent with a role in controlling ovarian function.

Authors:  R Penny; F Stanczyk; U Goebelsmann
Journal:  J Endocrinol Invest       Date:  1987-10       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.